BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31
BIODESIX INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.40−0.26 (-1.10%)
Close on Oct 19, 2026
- Market cap
- $240.93M
- P/E (TTM)
- –
- Dividend yield
- –
Biodesix statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Services-Medical Laboratories companies for comparison
Valuation
| Measure | Biodesix | Industry median |
|---|---|---|
| Market Cap | $246.90M | $1.07B |
| Enterprise Value | $263.72M | $1.35B |
| PS Ratio | 2.40 | 1.63 |
| PB Ratio | 27.00 | 3.19 |
Enterprise value
| Measure | Biodesix | Industry median |
|---|---|---|
| EV / Sales | 2.56 | 1.78 |
Income (trailing twelve months)
| Measure | Biodesix | Industry median |
|---|---|---|
| Revenue | $102.94M | $543.94M |
| Operating Income | -$20.61M | -$1.92M |
| Net Income | -$27.76M | -$1.32M |
| EBITDA | -$15.03M | -$29.24K |
| EPS (Diluted) | -$3.17 | -$0.02 |
Margins
| Measure | Biodesix | Industry median |
|---|---|---|
| Operating Margin | -20.0% | -4.46% |
| Profit Margin | -27.0% | -3.18% |
| EBITDA Margin | -14.6% | 2.41% |
| FCF Margin | -19.7% | 3.11% |
Returns
| Measure | Biodesix | Industry median |
|---|---|---|
| Return on Equity (ROE) | -540.0% | 0.49% |
| Return on Assets (ROA) | -30.3% | -3.06% |
| Return on Invested Capital (ROIC) | -61.4% | 1.25% |
| Return on Capital Employed (ROCE) | -25.7% | -2.29% |
Growth
| Measure | Biodesix | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 34.5% | 7.11% |
| Revenue Growth (3Y CAGR) | 32.3% | 10.9% |
| Revenue Growth (5Y CAGR) | 14.2% | 13.2% |
Balance sheet
| Measure | Biodesix | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $30.00M | $47.58M |
| Total Debt | $46.82M | $180.01M |
| Net Cash (Debt) | -$16.82M | $217.65K |
| Net Cash Per Share | -$1.59 | $0.01 |
| Equity (Book Value) | $9.14M | $189.59M |
| Book Value Per Share | $0.87 | $3.32 |
| Tangible Book Value | -$8.87M | $1.72M |
| Working Capital | $28.27M | $29.77M |
Financial position
| Measure | Biodesix | Industry median |
|---|---|---|
| Current Ratio | 2.85 | 1.41 |
| Quick Ratio | 2.56 | 0.97 |
| Debt / Equity | 5.12 | 0.66 |
| Interest Coverage | -2.55 | -0.90 |
Cash flow (trailing twelve months)
| Measure | Biodesix | Industry median |
|---|---|---|
| Operating Cash Flow | -$19.83M | $1.28M |
| Capital Expenditures | -$412.00K | -$16.47M |
| Free Cash Flow | -$20.24M | $23.23M |
| FCF Per Share | -$1.92 | $0.37 |
Efficiency
| Measure | Biodesix | Industry median |
|---|---|---|
| Asset Turnover | 1.12 | 0.83 |
| Revenue Per Employee | $308.20K | $218.24K |
| Profits Per Employee | -$83.12K | -$5.96K |
| Employee Count | 334 | 897 |
Dividends and yields
| Measure | Biodesix | Industry median |
|---|---|---|
| Earnings Yield | -11.2% | -1.25% |
| FCF Yield | -8.20% | 1.43% |
Shares
| Measure | Biodesix | Industry median |
|---|---|---|
| Shares Outstanding | 10,551,100 | 58,609,450 |
| Shares Change (YoY) | 21.3% | 2.64% |
| Shares Change (QoQ) | 4.38% | 0.29% |
| Shares Held by Institutions | 38.7% | 85.9% |
Taxes
| Measure | Biodesix | Industry median |
|---|---|---|
| Income Tax | $0 | $671.50K |
Scores
| Measure | Biodesix | Industry median |
|---|---|---|
| Altman Z-Score | -5.09 | 1.98 |
| Piotroski F-Score | 3 | 5 |
Calculated by StockData from Biodesix's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.